Placebo News and Research

RSS

Remicade helps those with ankylosing spondylitis

Data presented at the European League Against Rheumatism (EULAR) Annual European Congress of Rheumatology showed that patients with ankylosing spondylitis (AS) who received REMICADE, (infliximab) over two years experienced significant improvement in spinal mobility.

19 Jun 2007

Extended exposure to the psoriasis medication etanercept reduces psoriasis severity without increased adverse events

Extended exposure to the psoriasis medication etanercept does not appear to cause more infections or adverse events than placebo, and improvements in several measures of disease severity were observed for up to 96 weeks of therapy, according to a study in the June issue of Archives of Dermatology.

19 Jun 2007

Results of Tocilizumab study

Nearly half (43.9%) of rheumatoid arthritis (RA) patients receiving tocilizumab 8mg/kg, in addition to ongoing methotrexate therapy experienced a 50% (ACR50) improvement in symptoms at 24 weeks and more than one fifth achieved a 70% symptom improvement, according to results of a study presented at EULAR 2007, the Annual European Congress of Rheumatology in Barcelona, Spain.

19 Jun 2007

Analysis of steroids as a treatment for sudden hearing loss

Although steroids are the most widely used treatment for sudden hearing loss, little scientific evidence supports their use or that of any other therapies for this condition, according to a systematic review and meta-analysis both published in the June issue of Archives of Otolaryngology, Head & Neck Surgery.

19 Jun 2007

Bone erosion reduced by denosumab

Treatment with denosumab 60 mg and 180 mg (with background methotrexate) reduces the progression of bone erosion according to results of a 227 patient Phase II trial presented at EULAR 2007, the Annual European Congress of Rheumatology in Barcelona, Spain.

19 Jun 2007

OTC diet pill Alli now on sale in the U.S.

The first and only over-the-counter (OTC) product for weight loss approved by the Food and Drug Administration (FDA) has gone on sale in the U.S.

18 Jun 2007

Does Alli work?

The first and only over-the-counter product for weight loss approved by the Food and Drug Administration will be available Friday, June 15.

17 Jun 2007

New era of treatment for rheumatoid arthritis

Three new drugs for rheumatoid arthritis (RA) have ushered in a new era of treatment for this difficult and debilitating condition.

16 Jun 2007

Folic acid supplements do not reduce risk of precancerous colon tumors

Taking folic acid supplements does not reduce the risk of developing precancerous tumors in the colon and may even increase the risk, a new study has found.

16 Jun 2007

Zimulti (rimonabant) gets the thumbs down from FDA advisory panel

An advisory panel to the Food and Drug Administration (FDA) in the U.S. have unanimously voted that the federal agency should refuse approval for a new weight loss drug.

14 Jun 2007

Anticonvulsant medication gabapentin effective for fibromyalgia pain

New research supported by the National Institutes of Health's National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) shows that the anticonvulsant medication gabapentin, which is used for certain types of seizures, can be an effective treatment for the pain and other symptoms associated with the common, often hard-to-treat chronic pain disorder, fibromyalgia.

14 Jun 2007

FDA decision over new obesity drug hangs in the balance

The Food and Drug Administration (FDA) in the United States appears to be holding back on it's decision to grant approval for a weight loss drug.

11 Jun 2007

Low levels of testosterone may increase the long-term risk of death in men over 50 years old

"The new study is only the second report linking deficiency of this sex hormone with increased death from all causes, over time, and the first to do so in relatively healthy men who are living in the community," said Gail Laughlin, Ph.D., assistant professor and study author.

8 Jun 2007

Pramlintide treatment curbs fast food consumption and tendency to binge eat

The synthetic form of a hormone previously found to produce a feeling of fullness when eating and reduce body weight, also may help curb binge eating and the desire to eat high-fat foods and sweets.

8 Jun 2007

Folic acid does not decrease the risk of benign colorectal tumors

New research indicates that folic acid supplementation does not decrease the risk of benign colorectal tumors, but may possibly increase the risk for some types of colorectal tumors, according to a study in the June 6 issue of JAMA .

8 Jun 2007

Folic acid does not prevent colorectal cancer

Despite the fact that some previous studies have suggested that folate supplementation may help to prevent colorectal cancer, a new study says that is not the case and it may in fact increase the risk for some types of colorectal tumors.

6 Jun 2007

Chromium picolinate and biotin combo improves blood sugar control in people with type 2 diabetes

Nutrition 21, Inc. (NASDAQ: NXXI) today announced new published results from a 447 subject, randomized, double-blind, placebo-controlled clinical study that showed Diachrome, a patented combination of chromium picolinate and biotin, significantly improved glycemic control in patients with poorly controlled blood sugar levels who were being treated with oral anti-diabetic medication (OADs).

5 Jun 2007

Bone-targeting radioisotope radium-223 for prostate cancer treatment

The bone-targeting radioisotope radium-223 has delivered promising results in a randomised trial to test its efficacy in treatment of hormone-refractory prostate cancer (HRPC).

5 Jun 2007

Findings from study of immunotherapy vaccine in prostate cancer patients

Data from an ongoing study designed to explore the biologic and clinical activity of cancer immunotherapy sipuleucel-T, or Provenge, in patients with early stage recurrent prostate cancer who have a rising serum prostate specific antigen (PSA) level, but who have not yet developed metastatic disease will be presented by Oregon Health & Science University Cancer Institute researchers.

5 Jun 2007

Gabapentin reduces hot flashes in men receiving androgen deprivation therapy

North Central Cancer Treatment Group ( http://ncctg/ ) researchers based at Mayo Clinic ( http://www.mayo.edu/ ) in Rochester, Minn., have discovered that low doses of a drug used to prevent epileptic seizures and to treat nerve pain caused by shingles substantially reduces hot flashes in patients who are undergoing anti-hormonal treatment, or androgen-deprivation therapy, for prostate cancer.

5 Jun 2007